{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T00:09:42Z","timestamp":1722125382629},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clbc.2024.05.008","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T02:05:01Z","timestamp":1716257101000},"page":"527-532","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Axillary Management Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"Samir","family":"Mitri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estefania","family":"Roldan-Vasquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Borgonovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger B. Davis","family":"ScD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted A.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.clbc.2024.05.008_bib0001","first-page":"4808","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [published correction appears in","volume":"23","author":"Mamounas","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2024.05.008_bib0002","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/cncr.22540","article-title":"Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases","volume":"109","author":"Shen","year":"2007","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.clbc.2024.05.008_bib0003","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Alliance for clinical trials in oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.clbc.2024.05.008_bib0004","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.05.008_bib0005","unstructured":"American College of Surgeons. National Cancer Database. https:\/\/www.facs.org\/quality-programs\/cancer\/ncdb. Accessed 20 Jan 2020"},{"issue":"4","key":"10.1016\/j.clbc.2024.05.008_bib0006","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","article-title":"Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy","volume":"2","author":"Mougalian","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2024.05.008_bib0007","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.amjsurg.2016.07.018","article-title":"Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node positive breast cancer at diagnosis? An updated meta-analysis involving 3398 patients","volume":"212","author":"El Hage Chehade","year":"2016","journal-title":"Am. J. Surg."},{"issue":"11","key":"10.1016\/j.clbc.2024.05.008_bib0008","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","article-title":"Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy","volume":"27","author":"Montagna","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2024.05.008_bib0009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","article-title":"Axillary nodal management following neoadjuvant chemotherapy: A review","volume":"3","author":"Pilewskie","year":"2017","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2024.05.008_bib0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.amjsurg.2013.02.001","article-title":"Routine completion axillary lymph node dissection for positive sentinel nodes in patients undergoing mastectomy is not associated with improved local control","volume":"205","author":"Crawford","year":"2013","journal-title":"Am J Surg"},{"issue":"14","key":"10.1016\/j.clbc.2024.05.008_bib0011","first-page":"1","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"2045","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2024.05.008_bib0012","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","article-title":"Eight-year follow up result of the OTOASOR Trial: The Optimal Treatment Of the Axilla \u2013 Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. A randomized, single centre, phase III, non-inferiority trial","volume":"43","author":"S\u00e1volt","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2024.05.008_bib0013","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1245\/s10434-012-2386-3","article-title":"Characteristics and outcomes of sentinel node \u2013 positive breast cancer patients after total mastectomy without axillary-specific treatment","volume":"19","author":"Milgrom","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.05.008_bib0014","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jamcollsurg.2015.02.035","article-title":"Impact of the American College of Surgeons Oncology Group Z0011 randomized trial on the number of axillary nodes removed for patients with early-stage breast cancer","volume":"221","author":"Yao","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"11","key":"10.1016\/j.clbc.2024.05.008_bib0015","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","article-title":"How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study","volume":"23","author":"Mamtani","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2024.05.008_bib0016","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1245\/s10434-018-6345-5","article-title":"A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer","volume":"25","author":"Kantor","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2024.05.008_bib0017","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1245\/s10434-020-09382-w","article-title":"The role of oncotype DX\u00ae recurrence score in predicting axillary response after neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Pardo","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2024.05.008_bib0018","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1634\/theoncologist.11-8-857","article-title":"Adjuvant therapy with trastuzumab for HER-2\/neu-positive breast cancer","volume":"11","author":"Gonzalez-Angulo","year":"2006","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.clbc.2024.05.008_bib0019","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1245\/s10434-017-5969-1","article-title":"The impact of facility volume on rates of pathologic complete response to neoadjuvant chemotherapy used in breast cancer","volume":"24","author":"Ajmani","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2024.05.008_bib0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jamcollsurg.2016.08.541","article-title":"Neoadjuvant systemic therapy use for younger patients with breast cancer treated in different types of cancer centers across the united states","volume":"223","author":"Mohiuddin","year":"2016","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.clbc.2024.05.008_bib0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-018-4954-0","article-title":"The association of socioeconomic status with receipt of neoadjuvant chemotherapy","volume":"173","author":"Neuner","year":"2019","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924001216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924001216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T10:04:00Z","timestamp":1722074640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924001216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1526820924001216"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.05.008","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axillary Management Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}